datamatters24/research-document-archive huggingface dataset:
available clinical diagnostic laboratory 
test— 
‘‘(aa) provide for a sample 
that allows for the payment 
amounts established under para-
graph (2) of subsection (b) for 
such a test to be representative 
of rates paid by private payors to 
applicable laboratories receiving 
payment under this section, in-
cluding independent laboratories, 
hospital 
laboratories, 
hospital 
outreach laboratories, and physi-
cian office laboratories that fur-
nish the widely available clinical 
diagnostic laboratory test; 
‘‘(bb) include applicable in-
formation (as defined in para-
graph (3)) with respect to such 
widely available clinical diag-
nostic laboratory test from such 
different types of applicable lab-
oratories; and 
‘‘(cc) be of sufficient size to 
accurately 
and 
proportionally 
VerDate Sep 11 2014 
04:01 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1835.IH
H1835
pbinns on DSKJLVW7X2PROD with $$_JOB
(F) in subsection (k) by striking ‘‘The 
Committee’’ and inserting ‘‘Covered Commit-
tees’’. 
SEC. 107. ANNUAL REPORT AND PUBLIC DISCLOSURES. 
(a) REPORT ON FOREIGN LAWS AND PRACTICES.— 
Section 46106(b) of title 46, United States Code, is 
amended— 
(1) in paragraph (6)— 
(A) by striking ‘‘and’’ at the end; and 
(B) by striking ‘‘under this part’’ and in-
serting ‘‘under chapter 403’’; 
(2) in paragraph (7)— 
(A) by inserting ‘‘anticompetitive, non-
reciprocal trade, or’’ before ‘‘otherwise con-
cerning practices’’; 
(B) by inserting ‘‘or marine terminal oper-
ators’’ after ‘‘controlled carriers’’; and 
(C) by striking the period at the end and 
inserting a semicolon; and 
(3) by adding at the end the following: 
‘‘(8) an analysis of any trade imbalance result-
ing from the business practices of ocean common 
carriers, including an analysis of the data collected 
under section 41110; and
I 
118TH CONGRESS 
1ST SESSION H. R. 1922 
To provide for a limitation on availability of funds for Department of Labor, 
Employment and Training Administration, Training and Employment 
Services for fiscal year 2024. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 29, 2023 
Mr. BIGGS (for himself, Mr. ROSENDALE, Mr. GAETZ, Mr. GOOD of Virginia, 
Mr. ROY, and Mr. CRANE) introduced the following bill; which was re-
ferred to the Committee on Education and the Workforce 
A BILL 
To provide for a limitation on availability of funds for De-
partment of Labor, Employment and Training Adminis-
tration, Training and Employment Services for fiscal 
year 2024. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Sep 11 2014 
01:57 Apr 14, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1922.IH
H1922
pbinns on DSKJLVW7X2PROD with $$_JOB
I 
118TH CONGRESS 
1ST SESSION H. R. 1825 
To clarify that the Federal Right to Try law applies to schedule I substances 
for which a phase I clinical trial has been completed and to provide 
access for eligible patients to such substances pursuant to the Federal 
Right to Try law. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 28, 2023 
Mr. BLUMENAUER (for himself, Ms. MACE, Ms. DEAN of Pennsylvania, Mr. 
BIGGS, and Mr. CORREA) introduced the following bill; which was re-
ferred to the Committee on Energy and Commerce, and in addition to 
the Committee on the Judiciary, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
A BILL 
To clarify that the Federal Right to Try law applies to 
schedule I substances for which a phase I clinical trial 
has been completed and to provide access for eligible 
patients to such substances pursuant to the Federal 
Right to Try law. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Right to Try Clarifica-
tion Act’’. 
VerDate Sep 11 2014 
03:58 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1825.IH
H1825
pbinns on DSKJLVW7X2PROD with $$_JOB
‘‘(B) immunizations that have in effect a 
recommendation from the Advisory Committee 
on Immunization Practices of the Centers for 
Disease Control and Prevention with respect to 
the individual involved; 
‘‘(C) with respect to infants, children, and 
adolescents, evidence-informed preventive care 
and screenings provided for in the comprehen-
sive guidelines supported by the Health Re-
sources and Services Administration; 
‘‘(D) with respect to women, such addi-
tional preventive care and screenings not de-
scribed in subparagraph (A) as provided for in 
comprehensive guidelines supported by the 
Health Resources and Services Administration 
for purposes of this subparagraph; and 
‘‘(E) with respect to men who are age 40 
and over and are at high risk of developing 
prostate cancer (including African-American 
men and men with a family history of prostate 
cancer (as defined in paragraph (2))), such ad-
ditional evidence-based preventive care and 
screenings not described in subparagraph (A) 
for prostate cancer. 
VerDate Sep 11 2014 
03:58 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1826.IH
H1826
pbinns on DSKJLVW7X2PROD with $$_JOB
SEC. 2. FINDINGS. 
Congress finds as follows: 
(1) The Trickett Wendler, Frank Mongiello, 
Jordan McLinn, and Matthew Bellina Right to Try 
Act of 2017 (Public Law 115–176) was enacted in 
2018. 
(2) Section 561B of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 360bbb–0a), as added 
by the Act described in paragraph (1) (referred to 
in this section as the ‘‘Federal Right to Try law’’), 
does not exclude from the application of such law 
schedule I substances for which a phase I clinical 
trial has been completed. 
(3) Multiple schedule I drugs have progressed 
through phase I clinical trials and have been des-
ignated by the Food and Drug Administration as 
breakthrough therapies under section 506 of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
356) because of preliminary clinical evidence indi-
cating that such drugs demonstrate substantial im-
provement over existing therapies, but eligible pa-
tients have not been permitted access to these drugs 
pursuant to the Federal Right to Try law. 
SEC. 3. AMENDMENT TO FEDERAL RIGHT TO TRY LAW. 
Section 561B(b) of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360bbb–0a(b)) is amended by insert-
VerDate Sep 11 2014 
03:58 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1825.IH
H1825
pbinns on DSKJLVW7X2PROD with $$_JOB
ing ‘‘any provision of the Controlled Substances Act (21 
U.S.C. 801 et seq.) that prohibits the unauthorized use, 
possession, distribution, dispensation, or transportation of 
an eligible investigational drug,’’ before ‘‘and parts’’. 
Æ 
VerDate Sep 11 2014 
03:58 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H1825.IH
H1825
pbinns on DSKJLVW7X2PROD with $$_JOB
I 
118TH CONGRESS 
1ST SESSION H. R. 1827 
To prohibit the National Institutes of Health from conducting or supporting 
certain gain-of-function research, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 28, 2023 
Mr. CARTER of Georgia (for himself, Mr. CUELLAR, and Mr. GALLAGHER) in-
troduced the following bill; which was referred to the Committee on En-
ergy and Commerce 
A BILL 
To prohibit the National Institutes of Health from con-
ducting or supporting certain gain-of-function research, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Pausing Enhanced 
Pandemic Pathogen Research Act of 2023’’. 
VerDate Sep 11 2014 
03:58 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1827.IH
H1827
pbinns on DSKJLVW7X2PROD with $$_JOB
SEC. 2. NO CONDUCT OR SUPPORT BY NIH OF GAIN-OF- 
FUNCTION RESEARCH. 
Part A of title IV of the Public Health Service Act 
(42 U.S.C. 281 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 404P. GAIN-OF-FUNCTION RESEARCH. 
‘‘(a) PROHIBITION.—During the period ending on 
March 30, 2028, the National Institutes of Health shall 
not conduct or support, directly or indirectly, including 
through subgrants, any gain-of-function research. 
‘‘(b) LIMITATION.—This section does not apply to 
characterization or testing of any naturally occurring in-
fluenza virus or coronavirus, unless the characterization 
or testing could increase pathogenicity or transmissibility. 
‘‘(c) GAIN-OF-FUNCTION RESEARCH DEFINED.—In 
this section, the term ‘gain-of-function research’ means 
any research that could enhance the transmissibility, 
virulence, or pathogenicity of any pathogen (whether or 
not classified as a pathogen of pandemic potential) or non- 
pathogen agent in a way that could result in one or more 
of the following: 
‘‘(1) The pathogen or agent becoming mod-
erately or highly transmissible, virulent, or patho-
genic in human populations. 
‘‘(2) The pathogen or agent causing significant 
morbidity or mortality in humans. 
VerDate Sep 11 2014 
03:58 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1827.IH
H1827
pbinns on DSKJLVW7X2PROD with $$_JOB
‘‘(3) The pathogen or agent posing a severe 
threat to public health, the capacity of public health 
systems, or the national security of the United 
States.’’. 
Æ 
VerDate Sep 11 2014 
03:58 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H1827.IH
H1827
pbinns on DSKJLVW7X2PROD with $$_JOB
I 
118TH CONGRESS 
1ST SESSION 
H. R. 182 
To promote accountability and transparency in future executive orders. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 9, 2023 
Mr. MANN introduced the following bill; which was referred to the Committee 
on the Judiciary 
A BILL 
To promote accountability and transparency in future 
executive orders. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. NOTIFICATION RESPECTING CERTAIN EXECU-
TIVE ORDERS. 
(a) IN GENERAL.—Not later than 30 days before 
issuing a qualifying executive order, the President shall 
transmit to the Congress, and make publicly available, a 
notification with respect to such executive order. Such no-
tification shall contain— 
(1) the text of the executive order; 
VerDate Sep 11 2014 
00:37 Jan 19, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H182.IH
H182
kjohnson on DSK79L0C42PROD with BILLS
(2) the Federal law or laws affected by the ex-
ecutive order that is the subject of the notification; 
(3) how the President is working within the pa-
rameters specified in Federal law and the Constitu-
tion; 
(4) the means by which the executive order will 
be accomplished, including through any related Fed-
eral agencies or departments; and 
(5) a comprehensive list of organizations, busi-
nesses, and other parties or entities the President, 
or the President’s designee, engaged with prior to 
the issuance of such executive order. 
(b) REPORTS.—Not later than 6 months after the 
date of the enactment of this Act, and every 12 months 
thereafter, the President shall submit to the Congress a 
report on the outcome of each qualifying executive order 
issued during the period covered by the report. 
(c) QUALIFYING EXECUTIVE ORDER.—The term 
‘‘qualifying executive order’’ means any executive order 
(including an executive order that revokes or nullifies a 
previous executive order) issued on or after the date of 
the enactment of this Act, relating to the right of law- 
abiding individuals in the United States to own, carry, and 
VerDate Sep 11 2014 
00:37 Jan 19, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H182.IH
H182
kjohnson on DSK79L0C42PROD with BILLS
use firearms, as guaranteed by the Second Amendment 
to the Constitution. 
Æ 
VerDate Sep 11 2014 
00:37 Jan 19, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H182.IH
H182
kjohnson on DSK79L0C42PROD with BILLS
I 
118TH CONGRESS 
1ST SESSION H. R. 1830 
To prohibit a Federal firearms licensee from transferring a long gun to 
a person who the licensee knows or has reasonable cause to believe 
does not reside in (or if the person is a corporation or other business 
entity, does not maintain a place of business in) the State in which 
the licensee’s place of business is located. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 28, 2023 
Mr. CROW (for himself, Mr. RASKIN, Ms. NORTON, Mr. NEGUSE, and Ms. 
TLAIB) introduced the following bill; which was referred to the Committee 
on the Judiciary 
A BILL 
To prohibit a Federal firearms licensee from transferring 
a long gun to a person who the licensee knows or has 
reasonable cause to believe does not reside in (or if 
the person is a corporation or other business entity, 
does not maintain a place of business in) the State 
in which the licensee’s place of business is located. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Closing the Loophole 
on Interstate Firearm Sales Act’’. 
VerDate Sep 11 2014 
03:59 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1830.IH
H1830
pbinns on DSKJLVW7X2PROD with $$_JOB
Administration, Ex-Offender Activities for fiscal year 
2024 may not exceed $93,079,000. 
Æ 
VerDate Sep 11 2014 
03:08 Apr 14, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H1926.IH
H1926
pbinns on DSKJLVW7X2PROD with $$_JOB
VerDate Sep 11 2014 
01:49 Jun 05, 2024
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H192.PCS
H192
ssavage on LAPJG3WLY3PROD with BILLS
HR 1836 RFS
(C) appropriate data protections to ensure 
confidentiality of proprietary business informa-
tion; and 
(D) appropriate cybersecurity measures to 
protect data from unauthorized use; 
(2) incorporate data from stakeholders to facili-
tate— 
(A) the arrival, unloading, loading, and de-
parture of vessels; 
(B) cargo availability and pick up reserva-
tion; 
(C) chassis availability; and 
(D) other data elements the Commission 
consider prudent; and 
(3) consider relevant data standards used or 
under development within the private sector and 
whether to adopt or otherwise incorporate such 
standards into the rule finalized under this sub-
section, with priority given to standards that— 
(A) are developed in open, transparent, im-
partial, balanced, consensus-based processes; 
(B) are performance-based, technology 
neutral, and vendor neutral; 
VerDate Sep 11 2014 
08:19 Mar 23, 2024
Jkt 049200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H1836.RFS
H1836
kjohnson on DSK7ZCZBW3PROD with $$_JOB
surance and Employment Service Operations for fiscal 
year 2024 may not exceed $84,066,000. 
Æ 
VerDate Sep 11 2014 
03:10 Apr 14, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H1930.IH
H1930
pbinns on DSKJLVW7X2PROD with $$_JOB
A BILL 
To amend title 46, United States Code, to make technical 
corrections with respect to ocean shipping authorities, 
and for other purposes. 
VerDate Sep 11 2014 
02:42 Sep 27, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6652
E:\BILLS\H1836.RH
H1836
kjohnson on DSK7ZCZBW3PROD with $$_JOB
1829 
† HR 2670 EAS 
social workers, to support the mental health and well- 
being of— 
‘‘(A) any United States national unlawfully 
or wrongfully detained abroad; and 
‘‘(B) any family member of such United 
States national, with regard to the psychological, 
social, and mental health effects of such unlawful 
or wrongful detention. 
‘‘(4) NOTIFICATION
REQUIREMENT.—The Sec-
retary shall notify the Committee on Foreign Rela-
tions of the Senate, the Committee on Foreign Affairs 
of the House of Representatives, and the Committees 
on Appropriations of the Senate and the House of 
Representatives of any amount spent above $250,000 
for any fiscal year to carry out paragraphs (2) and 
(3). 
‘‘(5) REPORT.—Not later than 90 days after the 
end of each fiscal year, the Secretary shall submit to 
the Committees on Foreign Relations and Appropria-
tions of the Senate and the Committee on Foreign Af-
fairs and Appropriations of the House of Representa-
tives a report that includes— 
‘‘(A) a detailed description of expenditures 
made pursuant to paragraphs (2) and (3);
$4 by which the individual’s earnings derived from services 
for such month exceeds the amount specified for such 
month in clause (ii), except that such benefit may not be 
reduced below $0. 
‘‘(ii) The amount specified in this clause with respect 
to an individual for a month is the amount of earnings 
derived from services, applicable to the individual for such 
month under subsection (d)(4)(A), sufficient to dem-
onstrate the individual’s ability to engage in substantial 
gainful activity. 
‘‘(C) In the case of a benefit otherwise payable to 
an individual for a month under section 202 on the basis 
of the wages and self-employment income of an individual 
whose benefit is reduced pursuant to subparagraph (B), 
such benefit shall be reduced for such month by the same 
proportion as the reduction made pursuant to subpara-
graph (B).’’. 
(b) CONFORMING AMENDMENTS.—Section 223(a)(2) 
of such Act (42 U.S.C. 423(a)(2)) is amended by striking 
‘‘and section 215(b)(2)(A)(ii)’’ and inserting ‘‘, section 
215(b)(2)(A)(ii), and subsection (e) of this section’’. 
(c) EFFECTIVE DATE.—The amendments made by 
this section shall apply with respect to benefits payable 
for months beginning after the date that is 6 months after 
the date of the enactment of this Act. 
VerDate Sep 11 2014 
04:02 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1841.IH
H1841
pbinns on DSKJLVW7X2PROD with $$_JOB
(4) whether and to what extent the illicit supply 
of xylazine derives from the licit supply chain; and 
(5) recommendations for Congress with respect 
to whether xylazine should be transferred to another 
schedule under part B of the Controlled Substances 
Act (21 U.S.C. 811 et seq.). 
(b) ADDITIONAL REPORT.—Not later than 4 years 
after the date of the enactment of this Act, the Attorney 
General, acting through the Administrator of the Drug 
Enforcement Administration and in coordination with the 
Commissioner of Food and Drugs, shall submit to Con-
gress a report updating Congress on the prevalence of 
xylazine trafficking, misuse, and proliferation in the 
United States, including recommendations for Congress 
with respect to whether xylazine should be transferred to 
another schedule under part B of the Controlled Sub-
stances Act (21 U.S.C. 811 et seq.) or removed from 
schedule III of such part. 
(c) DEFINITION.—In this section, the term ‘‘illicit 
use’’ means any use described in section 424 of the Con-
trolled Substances Act, as added by section 3 of this Act. 
SEC. 7. DECLARATION OF EMERGING THREAT. 
Congress declares illicit xylazine use an emerging 
drug threat, as defined in section 702 of the Office of Na-
VerDate Sep 11 2014 
04:02 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H1839.IH
H1839
pbinns on DSKJLVW7X2PROD with $$_JOB
tional Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1701), in the United States. 
Æ 
VerDate Sep 11 2014 
04:02 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6301
E:\BILLS\H1839.IH
H1839
pbinns on DSKJLVW7X2PROD with $$_JOB
I 
118TH CONGRESS 
1ST SESSION 
H. R. 183 
To promote accountability and transparency in future executive orders. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 9, 2023 
Mr. MANN introduced the following bill; which was referred to the Committee 
on the Judiciary 
A BILL 
To promote accountability and transparency in future 
executive orders. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. NOTIFICATION RESPECTING CERTAIN EXECU-
TIVE ORDERS. 
(a) IN GENERAL.—Not later than 30 days before 
issuing a qualifying executive order, the President shall 
transmit to the Congress, and make publicly available, a 
notification with respect to such executive order. Such no-
tification shall contain— 
(1) the text of the executive order; 
VerDate Sep 11 2014 
00:37 Jan 19, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H183.IH
H183
kjohnson on DSK79L0C42PROD with BILLS
(2) the Federal law or laws affected by the ex-
ecutive order that is the subject of the notification; 
(3) how the President is working within the pa-
rameters specified in Federal law and the Constitu-
tion; 
(4) the means by which the executive order will 
be accomplished, including through any related Fed-
eral agencies or departments; and 
(5) a comprehensive list of organizations, busi-
nesses, and other parties or entities the President, 
or the President’s designee, engaged with prior to 
the issuance of such executive order. 
(b) REPORTS.—Not later than 6 months after the 
date of the enactment of this Act, and every 12 months 
thereafter, the President shall submit to the Congress a 
report on the outcome of each qualifying executive order 
issued during the period covered by the report. 
(c) QUALIFYING EXECUTIVE ORDER.—The term 
‘‘qualifying executive order’’ means any executive order 
(including an executive order that revokes or nullifies a 
previous executive order) issued on or after the date of 
the enactment of this Act, relating to any policy with re-
spect to immigration into the United States. 
Æ 
VerDate Sep 11 2014 
00:37 Jan 19, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H183.IH
H183
kjohnson on DSK79L0C42PROD with BILLS
I 
118TH CONGRESS 
1ST SESSION H. R. 1841 
To amend title II of the Social Security Act to establish a disability benefit 
offset for Purple Heart recipients, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 28, 2023 
Mr. AUSTIN SCOTT of Georgia (for himself, Mr. ALLEN, Mr. BACON, Mr. 
CARTER of Georgia, Mr. CARTER of Texas, Mr. CASTRO of Texas, Mr. 
CRAWFORD, Mr. DESJARLAIS, Mr. DUNCAN, Ms. ESCOBAR, Mr. FALLON, 
Mr. HUDSON, Mr. KELLY of Mississippi, Mr. KIM of New Jersey, Mrs. 
LESKO, Mr. MCHENRY, Mr. NEGUSE, Mr. PANETTA, Mr. DAVID SCOTT 
of Georgia, Ms. SLOTKIN, Mr. WALTZ, Mr. WITTMAN, Mr. WOMACK, Mr. 
ZINKE, Ms. GREENE of Georgia, and Mr. MCCORMICK) introduced the 
following bill; which was referred to the Committee on Ways and Means 
A BILL 
To amend title II of the Social Security Act to establish 
a disability benefit offset for Purple Heart recipients, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Purple Heart Freedom 
to Work Act’’. 
VerDate Sep 11 2014 
04:02 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1841.IH
H1841
pbinns on DSKJLVW7X2PROD with $$_JOB
SEC. 2. DISABILITY BENEFIT OFFSET FOR PURPLE HEART 
RECIPIENTS. 
(a) IN GENERAL.—Section 223(e) of the Social Secu-
rity Act (42 U.S.C. 423(e)) is amended— 
(1) in paragraph (1), by striking ‘‘(1) No ben-
efit’’ and inserting ‘‘(1)(A) Except as provided in 
paragraph (2), No benefit’’; 
(2) in paragraph (2)— 
(A) by striking ‘‘(2) No benefit’’ and in-
serting ‘‘(B) No benefit’’; and 
(B) by striking ‘‘paragraph (1)’’ and in-
serting ‘‘subparagraph (A)’’; and 
(3) by adding at the end the following: 
‘‘(2)(A) Notwithstanding subsection (a)(1) of this 
section, in any case in which an individual is entitled to 
a monthly insurance benefit under such subsection based 
on a disability that is attributable to an injury for which 
the individual was awarded the Purple Heart, such indi-
vidual shall be deemed to continue to be entitled to such 
benefit without regard to the individual’s termination 
month, except that payment of such benefit for any month 
shall be subject to the reduction described in subpara-
graph (B). 
‘‘(B)(i) Any benefit described in subparagraph (A) 
otherwise payable to an individual described in such sub-
paragraph for a month shall be reduced by $1 for each 
VerDate Sep 11 2014 
04:02 Apr 08, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1841.IH
H1841
pbinns on DSKJLVW7X2PROD with $$_JOB